Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Novatek reported for 6 months of 2023 by IFRS

7/26/23 NVTK

Yandex will create for Russia separate data markup service

7/26/23 YNDX

Moscow Exchange changes listing rules

7/26/23 MOEX

Teladoc reported for 6 months of 2023

7/26/23 TDOC

Visa reported for 9 months of fiscal year 2023

7/26/23 V

Alphabet has reported for 6 months of 2023

7/26/23 GOOG

Microsoft reported for fiscal year 2023

7/26/23 MSFT

Bank of Russia partially restricted withdrawal of funds from QIWI wallets

7/26/23 QIWI

The Visa announced a quarterly dividend

7/25/23 V

Etalon Group commissioned the second phase of the residential island Nagatino i-Land

7/25/23 ETLN